SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population

scientific article published on 20 May 2015

SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.12659/MSM.893007
P932PMC publication ID4450600
P698PubMed publication ID25992810
P5875ResearchGate publication ID277084555

P50authorMichal VrablíkQ17311886
Richard ČeškaQ47504165
P2093author name stringDana Dlouhá
Jaroslav A Hubáček
Vera Adámková
Ondřej Viklický
Petra Hrubá
Lukáš Zlatohlavek
P2860cites workSLCO1B1 variants and statin-induced myopathy--a genomewide studyQ29619028
SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic groupQ34047278
Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsQ34163351
Cerivastatin, genetic variants, and the risk of rhabdomyolysisQ34792178
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyQ35964012
The SLCO1B1*5 genetic variant is associated with statin-induced side effectsQ36158024
SLCO1B1 Polymorphisms and Statin-Induced MyopathyQ37410969
Statin myotoxicity: a review of genetic susceptibility factorsQ38157284
Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populationsQ38170960
Dyslipidaemia in 2013: New statin guidelines and promising novel therapeuticsQ38173637
Statin-associated myopathy: from genetic predisposition to clinical management.Q38271891
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.Q38454155
Global analysis of genetic variation in SLCO1B1.Q39340828
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.Q42757090
Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA.Q43062928
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyQ46130568
[The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic]Q51433897
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.Q54281855
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.Q54559255
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and RosuvastatinQ57825140
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidQ57825144
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinQ57825149
Impact of variants within seven candidate genes on statin treatment efficacyQ85272567
P304page(s)1454-1459
P577publication date2015-05-20
P1433published inMedical Science MonitorQ15756323
P1476titleSLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population
P478volume21

Reverse relations

cites work (P2860)
Q36256049Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies
Q57151967Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis
Q47676842Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study
Q35763066Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations
Q92156926Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components

Search more.